Overview

PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-04-28
Target enrollment:
Participant gender:
Summary
Phase I dose escalation period: solid tumors, including but not limited to biliary tract cancer, pancreatic cancer, ovarian cancer, thymoma, neuroendocrine carcinoma and other advanced solid tumors. Phase II trial period: biliary tract cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
SciClone Pharmaceuticals
Treatments:
Gemcitabine